Roquefort Therapeutics Announces £32m Reverse Takeover to Acquire Cancer Drug License

Key Facts

1Roquefort Therapeutics is acquiring an exclusive worldwide license for the cancer drug AO-252 for £32 million.

2The company plans to raise £8.5 million to fund its transformation into a clinical-stage oncology business.

3The deal is structured as a Reverse Takeover (RTO) and targets the TACC3 protein found in aggressive tumors.

Roquefort Therapeutics PLC (LSE:ROQ) has announced a transformative deal to acquire an exclusive worldwide license for the cancer drug AO-252. The transaction, valued at £32 million, is structured as a Reverse Takeover (RTO) and marks a significant shift in the company's strategic direction. To support this transition, the firm plans to raise £8.5 million in fresh capital to fund its evolution into a clinical-stage oncology business. The drug AO-252 is a small molecule targeting the TACC3 protein, which is frequently found in aggressive tumors. This move represents a substantial expansion for Roquefort, which was previously valued at less than £1.5 million. Investors are viewing the deal as a major milestone that provides both a high-potential clinical asset and the necessary capital for development.